Searchable abstracts of presentations at key conferences in endocrinology

ea0026s2.3 | Controversies in hyperaldosteronism | ECE2011

Non-surgical therapy of primary aldosteronism

Stowasser M

Unilateral laparoscopic adrenalectomy for unilateral primary aldosteronism (PA) results in cure of hypertension in 50–60% and improvement in all remaining patients. For those with bilateral PA or with unilateral PA but unsuitable for surgery, treatment with mineralocorticoid receptor (MR) blockers (spironolactone 12.5–50 mg/day or eplerenone 25–100 mg/day) or with sodium channel antagonists (amiloride 2.5–20 mg/day) is effective, but regular biochemical mon...

ea0026mte2 | (1) | ECE2011

Primary hyperaldosteronism

Stowasser M

It is now widely recognized that primary aldosteronism (PA) is much more common than previously thought, accounting for up to 5–10% of hypertensives with most patients normokalemic, and that aldosterone excess has adverse cardiovascular consequences that go above and beyond hypertension development. These findings have supported the concept that PA plays an important role in cardiovascular disease states and should be systematically sought and specifically treated. In rec...